The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 1 of the 11 sources its claims cite were checked for support.
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial
Open accessAbstract
Importance Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established. Objective To assess the efficacy of esketamine nasal spray plus an oral antidepressant compared with an oral antidepressant plus placebo nasal spray in delaying relapse of depressive symptoms in patients with TRD in stable remission after an induction and optimization course of esketamine nasal spray plus an oral antidepressant. Design, Setting, and Participants In this phase 3, multicenter, double-blind, randomized withdrawal study conducted from October 6, 2015, to February 15, 2018, at outpatient referral centers, 705 adults with prospectively confirmed TRD were enrolled; 455 entered the optimization phase and were treated with esketamine nasal spray (56 or 84 mg) plus an oral antidepressant. After 16 weeks of esketamine treatment, 297 who achieved stable remission or stable response entered the randomized withdrawal phase. Interventions Patients who achieved stable remission and those who achieved stable response (without remission) were randomized 1:1 to continue esketamine nasal spray or discontinue esketamine treatment and switch to placebo nasal spray, with oral antidepressant treatment continued in each group. Main Outcomes and Measures Time to relapse was examined in patients who achieved stable remission, as assessed using a weighted combination log-rank test. Results Among the 297 adults (mean age [SD]…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
36 Own result · 15 Own method · 6 No full text of the sources · 6 Own interpretation · 2 Sources not found · 2 No basis given · 1 Partly supported · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Results were consistent with previous findings from completed short-term (4-week) phase 2 and 3 studies.10,12,15”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Discussion
What the sources say
- Partly supportedcites [10] 10. Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: results of a double-blind, doubly-randomized, placebo-controlled study. JAMA Psychiatry. 2018;75(2):139-148. doi:10.1001/ jamapsychiatry.2017.3739 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the esketamine doses appeared safe, with no new or unexpected safety concerns. But the Design describes this as a phase 2 study with two one-week double-blind periods; the paper does not compare its safety results with completed four-week phase 2 and 3 studies. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [12] 12. Popova V, Daly E, Trivedi M, et al. Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs active control in treatment-resistant depression. Paper presented at: 2018 American Society for Clinical Pathology Annual Meeting; May 30, 2018; source
- Not checked — no full text of the sourcecites [15] 15. Fedgchin M, Trivedi M, Daly EJ, et al. Randomized, double-blind study of fixed-dose intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression (abstract 18). Presented at the 9th Biennial Conference of the International Society for Affective Disorders (ISAD) and the Houston Mood Disorders Conference; September 21, 2018; source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“No clinically significant change in electrocardiographic findings was observed during the study.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The HRs were 0.49 (95% CI, 0.27-0.90)for direct-entry patients and 0.45 (95% CI, 0.17-1.18)for transfer-entry patients.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Efficacy Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, among patients who achieved stable remission, 24 patients (26.7%) in the esketamine and antidepressant group and 39 patients (45.3%) in the antidepressant and placebo group experienced a relapse event during the maintenance phase”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Efficacy Results
plainn = 24- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, in a post hoc analysis, esketamine and antidepressant delayed relapse compared with antidepressant and placebo among patients who achieved stable remission and patients who achieved stable response combined (HR, 0.38; 95% CI, 0.26-0.57;P < .001).”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Efficacy Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On the basis of the C-SSRS, there were no reports of suicidal behavior in the optimization or maintenance phases.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 297 adults (mean age [SD], 46.3 [11.13] years; 197 [66.3%] female) who entered the randomized maintenance phase, 176 achieved stable remission; 24 (26.7%) in the esketamine and antidepressant group and 39 (45.3%) in the antidepressant and placebo group experienced relapse”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Abstract
plainn = 297- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“None of the patients who experienced relapse had a significant elevation in C-SSRS score (ie, the most severe postbaseline score was 2 for patients who experienced relapse in the esketamine and antidepressant group and 3 for patients who experienced relapse in the antidepressant and placebo group).”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No serious AEs considered as related to esketamine were reported during the optimization or maintenance phases.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The HRs were 0.49 (95% CI, 0.27-0.90)for direct-entry patients and 0.45 (95% CI, 0.17-1.18)for transfer-entry patients.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Efficacy Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 19
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Esketamine and antidepressant treatment decreased the risk of relapse by 51% (hazard ratio [HR], 0.49; 95% CI, 0.29-0.84)among patients who achieved stable remission”
- Also stated in: § Efficacy Results · plain
“Continued treatment with esketamine and antidepressant significantly delayed relapse compared with treatment with antidepressant and placebo (patients who achieved stable remission: HR, 0.49; 95% CI, 0.29-0.84;P = .003,number needed to treat [NNT], 6;”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Abstract
plaindirectn = 24- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Efficacy Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No cases of respiratory depression or interstitial cystitis were observed.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common adverse events reported for esketamine-treated patients after randomization weretransientdysgeusia,vertigo,dissociation,somnolence,anddizziness(incidence,20.4%-27.0%),each reported in fewer patients (<7%) treated with an antidepressant and placebo.”
- Also stated in: § Safety Results · plain
“The 5 most common AEs reported in the esketamine and antidepressant group during the maintenance phase were dysgeusia, vertigo, dissociation, somnolence, and dizziness (Table 3).”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Abstract
plainn = 297- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Safety Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Seven patients experienced 1 or more AEs during the maintenance phase, leading to discontinuation of the intranasal study drug; 4 (2.6%) of 152 were in the esketamine and antidepressant group (worsening depression, 3 patients; anxiety and confusional state [transient], 1 patient) and 3 (2.1%) of 145 were in the antidepressant and placebo group (worsening depression for each).”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Continued treatment with esketamine and antidepressant significantly delayed relapse compared with treatment with antidepressant and placebo (patients who achieved stable remission: HR, 0.49; 95% CI, 0.29-0.84;P = .003,number needed to treat [NNT], 6; patients who achieved stable response: HR, 0.30; 95% CI, 0.16-0.55:P < .001,NNT, 4).”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Efficacy Results
plaindirectn = 16 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On the basis of this analysis, the HR was estimated to range from 0.42 to 0.57, which is consistent with the overall HR of 0.47 (unweighted).”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Efficacy Results
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of those patients treated with esketamine and oral antidepressant who reported no suicidal ideation or behavior at baseline, 42 (11.6%)had a higher postbaseline score (maximum C-SSRS score of 1 ) in the optimization phase; and 3 (2.4%) had a higher postbaseline score (maximum C-SSRS score of 1 [n = 2] and 4 [n = 1]) compared with 6 patients (4.5%) receiving antidepressant and placebo (maximum C-SS”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plainn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Few patients experienced treatment-emergent transient hypertension, defined 0 100 80 Patients Without Relapse, % 60 40 20 0 100 80 Patients Without Relapse, % 60 40 20 B Patients who achieved stable response No. at risk Esketamine nasal spray and oral antidepressant Oral antidepressant and placebo nasal spray 0 90 86 84 69 74 52 58 41 53 34 39 28 31 22 25 19 20 12 14 10 10 7 8 4 7 3 7 3 6 3 5 3 2”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most direct-entry patients (362 [85.4%]) had baseline C-SSRS scores of 0, indicating no suicidal ideation or behavior.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After completing induction and optimization treatment (16 weeks total), in patients who achieved stable remission and those who achieved stable response, there was separation in MADRS total scores between patients randomized to continue vs discontinue esketamine treatment, each in the presence of antidepressant therapy, with MADRS total scores being lower over time for esketamine-treated patients.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Efficacy Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nineteen of the 39 relapses in patients who achieved stable remission and who were switched to placebo nasal spray occurred in the first month after discontinuation of esketamine treatment (6 by week 2 and the remainder by week 4), with 11 of these 19 early relapses occurring in patients who had required weekly treatment administration in the last 4 weeks of the optimization phase before randomiz”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Efficacy Results
plainn = 39- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were reported during the study.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most AEs were mild to moderate, observed after dosing, and generally resolved in the same day.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Transient blood pressure increases were observed with esketamine on treatment days; the maximum value was reached at 40 minutes after the start of administration in most cases and typically returned to the predose range by 1.5 hours after administration”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No symptoms or AEs of psychosis were observed.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Present-state dissociative symptoms, as measured by CADSS (eFigure 4 in Supplement 2), began shortly after the start of esketamine treatment, peaked at 40 minutes, and generally resolved by 1.5 hours.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Present-state dissociative symptoms, as measured by CADSS (eFigure 4 in Supplement 2), began shortly after the start of esketamine treatment, peaked at 40 minutes, and generally resolved by 1.5 hours.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Randomization was balanced using randomly permuted blocks and stratified by country.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Maintenance Phase
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients who achieved stable remission and those who achieved stable response (without remission) were separately randomized 1:1 according to a computer-generated schedule to continue esketamine treatment or discontinue esketamine treatment and switch to placebo nasal spray, each in addition to oral antidepressant treatment.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Maintenance Phase
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Even when patients with TRD respond to treatment, the overall relapse rate while continuing treatment with the same antidepressant is high after 2 (65%; within 3.1 months) and 3 failed trials (71.1%; within 3.3 months).3”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > D
What the sources say
- Not checked — no full text of the sourcecites [3] 3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163 (11):1905-1917. doi:10.1176/ajp.2006.163.11.1905 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Because patients with treatment resistance who achieve remission reportedly have lower relapse rates compared with those who respond but do not experience remission, 3 the prespecified primary analysis was conducted using the analysis of patients who achieved stable remission.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Maintenance Phase
What the sources say
- Not checked — no full text of the sourcecites [3] 3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163 (11):1905-1917. doi:10.1176/ajp.2006.163.11.1905 source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“One patient who did not meet stable remission or stable response criteria at the end of the optimization phase was incorrectly randomized in the group with stable response.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Conclusions
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The placebo solution contained a bittering agent (denatonium benzoate) to simulate the taste of esketamine solution and maintain the blinding.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Intranasal Study Drug and Administration
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The study was conducted in accordance with ethical principles of the Declaration of Helsinki, 16 Good Clinical Practices, and applicable regulatory requirements.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Study Population
What the sources say
- Not matchedcites [16] 16. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10. 1001/jama.2013.281053
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A 2-stage group-sequential design was implemented for the analysis set of patients who achieved stable remission, and an independent data-monitoring committee performed a prespecified interim analysis after 31 relapses to assess early efficacy.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Sample Size Determination
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Study limitations include the fact that esketamine has known transient dissociative and sedative effects that are difficult to blind; these symptoms could have biased the staff who observed treatment administration.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Institutional review boards and independent ethics committees (eAppendix 1 in Supplement 2) approved the study protocol and amendments.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Study Population
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Independent, blinded, remote raters performed MADRS assessments throughout the study (weeks 1, 2, and 4 of the screening and observation phase and weekly during the induction, optimization, maintenance, and follow-up phases).”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Efficacy Assessments
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“On the basis of assumptions (accrual period and rate, maximum study duration, and dropout rate), 211 patients who achieved stable remission needed to be randomized (1:1 ratio) to obtain 84 relapses, providing 90% power to detect a hazard ratio (HR) of 0.49 at a 2-sided α of .05 for a fixed-sample design to detect superiority of esketamine and antidepressant over antidepressant and placebo in delay”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Sample Size Determination
plainn = 211- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“The interim analysis on patients who achieved stable remission did not show superiority of esketamine and antidepressant over antidepressant and placebo (at a 2-sided significance level of .0097,log-rank test); therefore, the study continued, and the number of relapses in patients who achieved stable remission was reestimated to 59 relapses in total with an adjusted significance level of .046(2-s”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Sample Size Determination
What the sources say
- Not checked — no full text of the sourcecites [24] 24. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics. 1987;43(1):193-199. doi:10.2307/ 2531959 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Most censored patients (ie, when participation was ended) were considered as administrative based on the study having reached its end point (ie, based on the target number of relapse events having been achieved and the study stopping).Only 13 (8 patients who achieved stable remission and 5 patients who achieved stable response) in the esketamine nasal spray and oral antidepressant group and 12 (9”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Efficacy Results
plainn = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All patients provided written informed consent before entering the study.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Study Population
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“One patient who achieved stable response was incorrectly randomized as a patient who achieved stable remission at the end of the optimization phase.One patient did not meet stable remission or stable response criteria and was incorrectly randomized as a patient with stable response.”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Safety Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“or another clinically relevant event suggestive of relapse (assessed by a relapse adjudication committee).”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Efficacy End Points and Analyses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper relies on this without support.
Little is known about maintaining antidepressant effects of esketamine and ketamine in the long term.
“In contrast to available data about short-term antidepressant effects of esketamine and ketamine, 13,14 little is known about maintaining antidepressant effects in the long term.”
The paper relies on this without support.
This is the first controlled maintenance study of esketamine.
“We report the findings of, to our knowledge, the first controlled maintenance study of esketamine that evaluated whether continued use of intermittently administered esketamine nasal spray plus an oral antidepressant can sustain antidepressant effects among patients with TRD to a greater extent than an oral antidepressant alone.”
The paper relies on this without support.
There is a substantial unmet need for effective treatments that can sustain antidepressant benefits for the population with treatment-resistant depression.
“There is a substantial unmet need for effective treatments that can sustain antidepressant benefits for the population with TRD.”
The paper relies on this without support.
Esketamine plasma concentrations decrease rapidly for the initial 2 to 4 hours and more gradually thereafter, with a mean terminal half-life of 7-12 hours, and steady state is never reached with intermittent dosing.
“the decrease in esketamine plasma concentrations is rapid for the initial 2 to 4 hours and more gradual thereafter (mean terminal half-life, 7-12 hours), with steady state never reached with intermittent dosing.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A follow-up report observed that prolonged treatment (weekly or biweekly treatment) with (S)-ketamine nasal spray (56-84 mg; 16 weeks), in conjunction with an oral antidepressant (SSRI or a selective norepinephrine reuptake inhibitor [SNRI]), was well-tolerated with significant remission of symptoms.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Daly et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With regard to esketamine in particular, clinical use was largely based on four positive Phase 3 efficacy studies [62][63][64][65] that informed the subsequent FDA approval of intranasal esketamine for TRD and suicidal ideation with intent, as described above.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Induction trials largely ended at 4 weeks, while maintenance trials relied on designs that include enrichment (randomized withdrawal of responders/remitters) (22)”
From Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis (2026) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the continuation trial (NCT02493868 [12]), the primary outcome of remission remained consistent except when data from all Polish centers were excluded; in this case, the effect size decreased and the analysis was not statistically significant.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across clinical trials, ketamine and esketamine reliably produce rapid symptom relief, yet responses frequently decay within days to weeks, with high relapse rates following discontinuation [81,82,83].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [83]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Further, patients who were in remission were more likely to relapse when switched to a placebo nasal spray in conjunction with an oral antidepressant”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Daly et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“Maintenance regimens extend benefit for some patients but only partially offset this erosion [82,83,84].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [83]
The cited source says what the claim attributes to it.
In the citing paper
“randomized-withdrawal designs answer a relapse-prevention question in an enriched population, not an initiation question in an unselected TRD population (22)”
The cited source says what the claim attributes to it.
In the citing paper
“Our findings are concordant with the direction and general magnitude of effect reported in pivotal trials of adjunctive intranasal esketamine in TRD and the relapse-prevention study (18–23)”
In the citing paper
“Two maintenance studies followed patients on maintenance esketamine up to 88 weeks, and reported decreased risk of depressive relapse when patients used esketamine weekly or every second week,74 and provided reassuring data on safety to over 1 year of esketamine use.75”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [74]
In the citing paper
“However, when reviewing the major esketamine trials, significantly increased rates of somnolence versus placebo have been reported, especially in relapse-prevention studies,74,152 but this has not been seen consistently.153”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [74]
In the citing paper
“Repeated dosing of ketamine is more efficacious in clinical trials than typical antidepressants alone [109, 110].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [109]
In the citing paper
“A recent, longer (4 months) clinical trial by Daly and colleagues demonstrated a significant dose–response curve associated with esketamine augmentation [112].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [112]
In the citing paper
“Findings regarding both safety and efficacy in the trial are of limited applicability due to a high dropout rate [112].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [112]
In the citing paper
“Long-term esketamine use in Daly and colleagues’ study was also linked to short-term, adverse effects, including increases in blood pressure, dissociative experiences, and incidents of worsening depression when compared with placebo.”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [112]
In the citing paper
“The approvals of esketamine nasal spray were based on efficacy and safety findings from phase 2/3 studies of TRD treatment for 4 weeks to 1 year [9–14].”
In the citing paper
“The interim efficacy results from SUSTAIN-3 are consistent with the results of a trial testing the maintenance efficacy of esketamine plus oral antidepressant using a randomized withdrawal design [10].”
In the citing paper
“Although 'treatment-resistant depression' sounds rare and severe, Janssen's definition, consisting of people who have 'failed' two different antidepressants, is likely to encompass many current antidepressant users.17”
From Are we repeating mistakes of the past? A review of the evidence for esketamine (2021) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Maintenance Phase
“At week 16 of the optimization phase, esketamine-treated direct-entry (open-label treatment) and transfer-entry patients (double-blind treatment) who had achieved stable remission”
§ Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial > Transfer-Entry and Direct-Entry Patients
“entered a 12-week optimization phase”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Diagnostic and Statistical Manual of Mental Disorders(DSM)
Leong, F. T. L. (2008) · Sage eBooks · doi:10.4135/9781412963978.n182 · Cited by 10,861
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,825
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“The study consisted of up to 5 phases: (1) a 4-week screening and prospective observation phase (direct-entry patients only); (2) a 4-week open-label induction phase (direct-entry patients only); (3) a 12-week optimization phase (open-label, directentry patients or double-blind, transfer-entry patients); (4) a mainten…”
MethodSelf-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationWalker, E. R., McGee, R. E., & Druss, B. G. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2502 · Cited by 2,976
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Posner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Cited by
Sorted by citations
Items 101–116 of 116
Esketamine for treatment resistant depression
Jauhar, S., & Morrison, P. (2019) · BMJ · doi:10.1136/bmj.l5572 · Cited by 40
Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression
Fancy, F., Rodrigues, N. B., Di Vincenzo, J. D., Chau, E. H., Sethi, R., Husain, M. I., Gill, H., Tabassum, A., Mckenzie, A., Phan, L., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13284 · Cited by 40
Castro, M., Wilkinson, S. T., Al Jurdi, R. K., Petrillo, M. P., Zaki, N., Borentain, S., Fu, D. J., Turkoz, I., Sun, L., Brown, B., et al. (2023) · CNS Drugs · doi:10.1007/s40263-023-01026-3 · Cited by 25
Morrens, J., Mathews, M., Popova, V., Borentain, S., Rive, B., Gonzalez Martin Moro, B., Jamieson, C., & Zhang, Q. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s358367 · Cited by 24
Zhou, Y., Liu, W., Zheng, W., Wang, C., Zhan, Y., Lan, X., Zhang, B., Zhang, C., & Ning, Y. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.001 · Cited by 23
Surjan, J., Grossi, J. D., Del Porto, J. A., Delfino, R. S., de Oliveira Cerqueira, R., Lucchese, A. C., Magalhães, E., Del Sant, L. C., Tuena, M. A., Nakahira, C., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01193-z · Cited by 19
Denee, T., Ming, T., Waller, J., Bailey, T., Rajkovic-Hooley, O., Middleton-Dalby, C., Le, H. H., Zhang, Q., McCrone, P., & Taylor, D. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1857580 · Cited by 12
Di Vincenzo, J. D., Lipsitz, O., Rodrigues, N. B., Lee, Y., Gill, H., Kratiuk, K., Subramaniapillai, M., Mansur, R., McIntyre, R. S., & Rosenblat, J. D. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.09.002 · Cited by 12
Ouyang, Y., & Li, J. (2025) · Medicine · doi:10.1097/md.0000000000041495 · Cited by 10
Young, A. H., Llorca, P.-M., Fagiolini, A., Falkai, P., Cardoner, N., Nielsen, R. E., Blomqvist, O., Godinov, Y., Rive, B., Diels, J., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.124 · Cited by 9
Self-citationNew Somatic Treatments for Child and Adolescent Depression
Cullen, K. R., Padilla, L. E., Papke, V. N., & Klimes-Dougan, B. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-019-00194-8 · Cited by 5
Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui
Mathews, M., Daly, E. J., Popova, V., Heerlein, K., Canuso, C., & Drevets, W. C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796020000268 · Cited by 7
Self-citationNaudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025) · BMC Medicine · doi:10.1186/s12916-025-04435-x · Cited by 6
“In the continuation trial (NCT02493868 [12]), the primary outcome of remission remained consistent except when data from all Polish centers were excluded; in this case, the effect size decreased and the analysis was not statistically significant.”
InfluentialTaillefer de Laportalière, T., Horowitz, M. A., Soeiro, T., Lepetit, M., Jullien, A., Yrondi, A., Moncrieff, J., Naudet, F., & Montastruc, F. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.03.009 · Cited by 2
Xie, J., Pu, C., & Sun, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1774549 · Cited by 1
“A pivotal relapse-prevention trial used a randomized-withdrawal design in stabilized responders/remitters, assessing whether continuing esketamine plus oral antidepressant delays relapse compared with switching to placebo nasal spray while continuing the oral antidepressant (22).”
InfluentialSynaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Metadata
- Authors
- Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., Thase, M. E., Zajecka, J., Winokur, A., Divacka, I., Fagiolini, A., Cubala, W. J., Bitter, I., Blier, P., Shelton, R. C., Molero, P., Manji, H., Drevets, W. C., & Singh, J. B.
- Affiliations
- Department of Neuroscience, Janssen Research and Development LLC, Titusville, New Jersey
- The University of Texas Southwestern Medical Center (US)
- Department of Neuroscience, Janssen Research and Development LLC, San Diego, California
- Department of Clinical Biostatistics, Janssen Research and Development LLC, Fremont, California
- Janssen Research & Development (United States) (US)
- Department of Clinical Biostatistics, Janssen Research and Development LLC, Titusville, New Jersey
- University of Pennsylvania (US)
- Rush University Medical Center (US)
- UConn Health (US)
- Private practice, Prague, Czech Republic
- University of Siena (IT)
- Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
- Semmelweis University (HU)
- University of Ottawa (CA)
- University of Alabama (US)
- Clinica Universidad de Navarra (ES)
- Corresponding author
- Daly, Ella J.
- ORCID
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2019-09-01
- Volume
- 76
- Issue
- 9
- Pages
- 893
- ISSN
- 2168-622X (ISSN-L)
- PMC
- PMC6551577
- OpenAlex
- W2948816951
- Semantic Scholar
- a466e4d3128df9d49edb7484ee67fd7b3ab3d49c
- Cited by
- 795
- References
- 27
- Citations by year
- 2026: 98 · 2025: 110 · 2024: 104 · 2023: 81 · 2022: 69 · 2021: 79 · 2020: 236 · 2019: 16
- FWCI
- 61.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Psychiatry (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Cancer Prevention and Research Institute of Texas
- Patient-Centered Outcomes Research Institute
- Sunovion
- Cerecor
- Otsuka America
- University of Oxford
- H. Lundbeck A/S
- Gobierno de Navarra
- Agency for Healthcare Research and Quality
- Allergan
- National Institute of Mental Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- Janssen Research and Development
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, treatment-resistant depression, relapse prevention, maintenance therapy, nasal spray, oral antidepressant, sustained remission, long-term efficacy, depression recurrence, ketamine
- MeSH terms
- Administration, Intranasal, Administration, Oral, Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Ketamine, Male, Middle Aged, Remission Induction, Outcome Assessment, Health Care, Secondary Prevention, Nasal Sprays, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
